In rare class action trial, jury finds Puma Biotech liable for fraud – but Puma claims victory [Reuters]
Puma Biotechnology Inc (PBYI)
Last puma biotechnology inc earnings: 2/20 04:07 pm
Check Earnings Report
US:NYSE Investor Relations:
pumabiotechnology.com/ir.html
Company Research
Source: Reuters
In rare class action trial, jury finds Puma Biotech liable for fraud – but Puma claims victory | Reuters 10 Min Read (Reuters) - On Monday, after eight days of trial and nearly four days of deliberation, a federal jury in Santa Ana, California found the pharmaceutical company Puma Biotechnology and its CEO, Alan Auerbach, liable for securities fraud for a statement Auerbach made on a call with stock analysts in July 2014. The jury said Auerbach knowingly misrepresented clinical trial results on the disease-free survival rate of breast cancer patients treated with the drug neratinib, which is intended to prevent recurrences in patients who have already received chemotherapy. Puma’s share price, according to jurors, was inflated by $4.50 per share as a result of the fraud. That is the factual outcome of this rare securities class action trial, only the 15th shareholder fraud class action to be tried to a verdict since the passage of the Private Securities Litigation Reform Act in 1995.
Show less
Read more
Impact Snapshot
Event Time:
PBYI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBYI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBYI alerts
High impacting Puma Biotechnology Inc news events
Weekly update
A roundup of the hottest topics
PBYI
News
- Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial ResultsBusiness Wire
- Puma Biotech (PBYI) Stock Dips While Market Gains: Key Facts [Yahoo! Finance]Yahoo! Finance
- Puma Biotechnology, Inc. (NASDAQ: PBYI) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Puma Biotechnology (NASDAQ:PBYI) shareholders have earned a 93% return over the last year [Yahoo! Finance]Yahoo! Finance
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business Wire
PBYI
Earnings
- 2/29/24 - Miss
PBYI
Analyst Actions
- 2/13/24 - HC Wainwright
PBYI
Sec Filings
- 3/29/24 - Form SC
- 3/19/24 - Form 4
- 3/19/24 - Form 8-K
- PBYI's page on the SEC website